Page 197 - 2021_07-Haematologica-web

Lenalidomide induction and maintenance in MM
ubiquitin ligase complex CRL4. Br J
Haematol. 2014;164(6):811-821. 14.Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma
cells. Science. 2014;343(6168):301-305.
15. Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in mul- tiple myeloma cells by regulation of c-Myc
and IRF4. Blood Cancer J. 2015;5:e354.
16. Wu P, Davies FE, Horton C, et al. The com- bination of cyclophosphomide, thalido- mide and dexamethasone is an effective alternative to cyclophosphamide - vin- cristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autolo- gous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma.
2006;47(11):2335-2338.
17. Morgan GJ, Davies FE, Gregory WM, et al.
Cyclophosphamide, thalidomide, and dex- amethasone as induction therapy for newly diagnosed multiple myeloma patients des- tined for autologous stem-cell transplanta- tion: MRC Myeloma IX randomized trial results. Haematologica. 2012;97(3):442- 450.
18. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX Trial: survival outcomes with bisphospho- nate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030-6038.
19. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
20. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplan- tation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
21. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide ther- apy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012; 119(1):7-15.
22.Jackson GH, Davies FE, Pawlyn C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dex- amethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(12):e616-e629.
23.Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observa- tion for patients with newly diagnosed multiple myeloma (Myeloma XI): a multi- centre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73.
24. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphospho- nate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030-6038.
25. Kumar SK, Lacy MQ, Hayman SR, et al. Lenalidomide, cyclophosphamide and dex- amethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011;86(8):640-645.
26. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexametha- sone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007;137(3):268-269.
27.Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a compara- tive analysis of 411 patients. Blood. 2010;115(7):1343-1350.
28. Luo J, Gagne JJ, Landon J, et al. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer. 2017;70:22-33.
29.Zweegman S, van der Holt B, Mellqvist UH, et al. Melphalan, prednisone, and lenalidomide versus melphalan, pred- nisone, and thalidomide in untreated multi- ple myeloma. Blood. 2016;127(9):1109- 1116.
30. Stewart AK, Jacobus S, Fonseca R, et al. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015;126(11):1294-1301.
31. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-2955.
32. Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721-9.
33.Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHE- MA/GEM study. Blood. 2012;120(8):1589- 1596.
34. Cavo M, Pantani L, Pezzi A, et al. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib- cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelo- ma. Leukemia. 2015;29(12):2429-2431.
35.Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of borte- zomib, dexamethasone, cyclophos- phamide, and lenalidomide in previously
untreated multiple myeloma. Blood. 2012;
119(19):4375-4382.
36.Moreau P, Attal M, Hulin C, et al.
Bortezomib, thalidomide, and dexametha- sone with or without daratumumab before and after autologous stem-cell transplanta- tion for newly diagnosed multiple myelo- ma (CASSIOPEIA): a randomised, open- label, phase 3 study. Lancet. 2019; 394(10192):29-38.
37. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autolo- gous stem-cell transplantation in newly diagnosed multiple myeloma: a meta- analysis. J Clin Oncol. 2017;35(29):3279- 3289.
38. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autolo- gous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017; 4(9): e431-e442.
39. Ozaki S, Harada T, Saitoh T, et al. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autolo- gous stem cell transplantation. A multicen- ter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network [Multicenter Study]. Acta Haematol. 2014;132(2):211- 219.
40.Minoia C, Pisapia G, Palazzo G, et al. Impact of novel agents followed by autolo- gous hematopoietic stem cell transplanta- tion for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis. Bone Marrow Transplant. 2015;50(11):1486.
41.Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myelo- ma: spotlight review. Leukemia. 2009; 23(12):2210-2221.
42. Avet-Loiseau H, Facon T. Front-line thera- pies for elderly patients with transplant- ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018;32(6):1267-1276.
43.Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalido- mide therapy for newly diagnosed myelo- ma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333-342.
44.Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506.
45. Abonour R, Wagner L, Durie BGM, et al. Impact of post-transplantation mainte- nance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018;97(12):2425-2436.
haematologica | 2021; 106(7)
1967